Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
Delayed Swiss Exchange  -  11:31 2022-10-06 am EDT
0.0286 CHF   -1.38%
01:38aRelief Therapeutics Chooses Exclusive US Distributor For PKU GOLIKE
MT
01:04aRelief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
EQ
10/03Relief Therapeutics Partner Acer To Secure US Patent For Phenylbutyrate-Sodium Benzoate Kit
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

08/17/2022 | 01:04am EDT

Relief Therapeutics Holding SA / Key word(s): Personnel
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

17-Aug-2022 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

Experienced Leader in Market Access to Bolster Relief’s U.S. Commercial Operations


Geneva, Switzerland, August 17, 2022 RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic benefit from serious diseases with high unmet need, announced today the appointment of David McCullough as Senior Director and Head of U.S. Market Access, effective August 22nd. In this newly created position, reporting to Anthony Kim, Senior Vice President and Head of U.S. Commercial Operations, Mr. McCullough will direct Relief’s market access strategy and operations to ensure timely and effective access to Relief’s products for patients in the U.S.

“David’s appointment as Head of U.S. Market Access signifies an important milestone for Relief, as we have now completed the hiring of the U.S. Commercial Team and are one step closer to providing patient access to treatments for diseases with high unmet medical needs,” stated Mr. Kim. “As we continue to grow, David’s more than 20 years of extensive commercial experience working with payors, physicians and specialty pharmacies to help ensure access for patients and their families, will be invaluable. With expertise and relationships forged during his tenures at Mirum Pharmaceuticals, Inc., Novartis Gene Therapies, Spark Therapeutics and other companies, we look forward to leveraging his broad knowledge of market access in preparation for our October 2022 U.S. launch of PKU GOLIKE®. With continued commercialization of Relief products on the horizon, David serves as a welcome addition to our commercial leadership team.”

“Relief’s mission to develop a robust therapeutic portfolio for rare and ultra-rare diseases synergistically aligns with my desire to increase patient access to rare disease treatment options,” added Mr. McCullough. “I look forward to contributing to the commercial sales of PKU GOLIKE® and additional products in Relief’s pipeline.”

Prior to joining Relief, Mr. McCullough served as National Account Director (Payer Account Lead) at Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of rare diseases, where he was responsible for building out the company’s Medicaid launch strategy and supporting the expansion of key market access policies. Previously, he held several positions of increasing responsibility at Novartis Gene Therapies (formerly AveXis), most recently, as Director National Accounts, where he was responsible for successfully negotiating multiple Value-Based Agreements and 10 state Medicaid policies. Before that, he worked as a Patient Access Liaison at Spark Therapeutics, supporting the launch of a first-of-its-kind gene therapy in the inherited retinal disease space and also aided in the build-out of patient services and market access operations. Before Spark Therapeutics, Mr. McCullough was Associate Director, Patient Services Southeast at Shire. Earlier in his career, Mr. McCullough held numerous market access and commercial operations positions at various biotechnology and pharmaceutical companies, including an Institutional Specialty Manager at MedImmune and a Territory Manager at Abbott Laboratories.

Mr. McCullough earned a BA in Speech/Public Relations from McNeese State University, a BS in Ministry and Theology from St. Louis Christian College, and served four years in the United States Coast Guard.

 

About RELIEF THERAPEUTICS Holding SA

Relief is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of metabolic, dermatological and pulmonary rare diseases with a portfolio of clinical and marketed assets that serve unmet patient needs. Relief has a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including UCDs and Maple Syrup Urine Disease (MSUD). Relief also continues to develop aviptadil for several rare pulmonary indications. Relief's 2021 acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH brought to Relief a diverse pipeline of marketed and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com and follow Relief on LinkedIn.

 

 
CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com
 
FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
 

 

 

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including those risks discussed in RELIEF THERAPEUTICS Holding SA's filings with the SIX and the U.S. Securities and Exchange Commission, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


Additional features:


File: Ad hoc release

End of Inside Information
Language: English
Company: Relief Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Switzerland
Phone: +41 22 545 11 16
E-mail: contact@relieftherapeutics.com
Internet: https://relieftherapeutics.com
ISIN: CH0100191136
Valor: 10019113
Listed: SIX Swiss Exchange
EQS News ID: 1421917

 
End of Announcement EQS News Service

1421917  17-Aug-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1421917&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about RELIEF THERAPEUTICS HOLDING AG
01:38aRelief Therapeutics Chooses Exclusive US Distributor For PKU GOLIKE
MT
01:04aRelief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
EQ
10/03Relief Therapeutics Partner Acer To Secure US Patent For Phenylbutyrate-Sodium Benzoate..
MT
10/03Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US..
EQ
09/22Relief Therapeutics Gets US Approval to Launch Pilot Trial For Skin Disease Treatment
MT
09/22Relief Therapeutics Holding AG Announces IRB Approval and Initiation of an Investigator..
CI
09/22Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated ..
EQ
09/15Relief Therapeutics Holding AG Reports Earnings Results for the Half Year Ended June 30..
CI
09/15Relief Therapeutics Posts Wider Attributable Loss In H1
MT
09/15Relief Reports Half-Year 2022 Results and Provides Corporate Update
EQ
More news
Financials
Sales 2021 3,32  3,36  3,36 
Net income 2021 -34,7 M -35,1 M -35,1 M
Net cash 2021 40,5 M 41,0 M 41,0 M
P/E ratio 2021 -6,44x
Yield 2021 -
Capitalization 120 M 121 M 121 M
EV / Sales 2020 -
EV / Sales 2021 70 411 988x
Nbr of Employees 10
Free-Float 60,5%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 0,03
Average target price
Spread / Average Target -
Managers and Directors
Jack M. Weinstein Chief Financial Officer & Treasurer
Raghuram Selvaraju Chairman
Nermeen Varawalla Chief Medical Officer
Taneli Jouhikainen Chief Operating Officer
Thomas Plitz Director
Sector and Competitors
1st jan.Capi. (M$)
RELIEF THERAPEUTICS HOLDING AG-53.38%123
MODERNA, INC.-50.54%49 142
LONZA GROUP AG-33.72%38 001
IQVIA HOLDINGS INC.-31.78%35 901
SEAGEN INC.-11.47%25 244
ALNYLAM PHARMACEUTICALS, INC.18.67%24 128